// App-Quantinova.ai

3002 : Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors.

Researchers

Presenter

  • Anthony W. Tolcher

Principal Investigators

  • Mario Sznol

  • Siwen Hu-Lieskovan

  • Kyriakos P. Papadopoulos

  • Amita Patnaik

  • Drew W. Rasco

  • Donna Di Gravio

  • Bo Huang

  • Dhiraj Gambhire

  • Ying Chen

  • Nuzhat Pathan

  • Kai Wang

  • Emmett V. Schmidt

  • Laura Quan Man Chow

Medical Centers

  • START San Antonio, San Antonio, TX

  • Yale University, New Haven, CT

  • Ronald Reagan UCLA Medical Center, Los Angeles, CA

  • START Center for Cancer Care, San Antonio, TX

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • Pfizer Inc, Collegeville, PA

  • Pfizer Oncology, Groton, CT

  • Pfizer Oncology, Cambridge, MA

  • Pfizer Oncology, La Jolla, CA

  • Pfizer Inc, San Diego, CA

  • Pfizer Inc, San Diego, CA

  • Merck & Co., Inc., Kenilworth, NJ

  • University of Washington, Seattle, WA

Locations

  • United States

Companies

  • PharmAbcine Inc.

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • PF-05082566

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02179918

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved